Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.11.25.690563

TRPV4 Promotes Histamine Receptor Signaling in Lymphatic Endothelial Cells

Abstract

BackgroundThe control of lymphatic permeability and flow is essential for homeostatic regulation of tissue fluid balance and immune responses. Histamine has been identified as an important signaling mediator involved in the regulation of lymphatic function. Histamine is released from activated perilymphatic mast cells and may also be produced by lymphatic endothelial cells (LECs) in response to flow-induced shear stress. The non-selective cation channel Transient Receptor Potential Vanilloid 4 (TRPV4) is an important mediator of signaling by GPCRs, including histamine receptors. TRPV4 is activated in response to shear stress and is functionally expressed by LECs. We hypothesized that histamine receptors and TRPV4 interact in LECs, leading to activation of distinct downstream signaling pathways. This study examined the mechanistic link between TRPV4 activity and histaminergic signaling in LECs. Principle ResultsHistaminergic Ca2+ signaling was examined in primary human LECs. Responses to histamine were mainly driven by the H1R histamine receptor, with some contribution by the H4R subtype, as determined using selective antagonists. H4R signaling in response to 4-methylhistamine was effectively prevented by either removal of extracellular Ca2+ or block of TRPV4 activity, consistent with TRPV4-dependence. Conversely, activation of H4R resulted in marked sensitization of subsequent responses to the selective TRPV4 agonist GSK1016790A. This interaction was mediated through a PLA2-dependent mechanism. TRPV4 activity was required for histamine receptor-evoked translocation of the Ca2+-dependent transcription factor NFATc1 and for cytoskeletal remodeling. By contrast, the release of cytokines in response to activation of either histamine receptors or TRPV4 were largely independent processes. ConclusionsThis study identifies TRPV4 as an important mediator of histaminergic signaling in LECs. The findings provide further support for the involvement of TRPV4 in defining the nature and magnitude of endothelial signaling downstream of GPCRs. HighlightsO_LIHistamine receptors are functionally expressed by primary human LECs C_LIO_LITRPV4 is an important driver of H4R-evoked Ca2+ signaling in LECs C_LIO_LIHistamine receptor activation sensitizes TRPV4 signaling in LECs C_LIO_LITRPV4 promotes histamine-evoked NFATc1 translocation to the nucleus of LECs C_LIO_LIHistamine and TRPV4 evoked cytokine release from LECs involve distinct mechanisms C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=115 SRC="FIGDIR/small/690563v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@409b49org.highwire.dtl.DTLVardef@192f58dorg.highwire.dtl.DTLVardef@136fdd0org.highwire.dtl.DTLVardef@15175c6_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical abstract.C_FLOATNO Histamine exerts its effects on lymphatic endothelial cells through interaction with the H1R and H4R receptor subtypes. H1R activation promotes Ca2+ release from intracellular stores. Activation of the H4R leads to elevated intracellular Ca2+ through crosstalk with the non-selective cation channel TRPV4. Interaction between H4R and TRPV4 is mediated through a PLA2-dependent mechanism. TRPV4 enhances histamine-evoked NFATc1 activation and translocation and cytoskeletal remodeling. In contrast, histamine receptor- and TRPV4-mediated cytokine release appear to involve mechanistically independent processes. C_FIG

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Retamal, J. S., Peng, S., Nguyen, T.-N., Bandala-Sanchez, E., Eriksson, E. M., McCague, R. E., Mahdavian, N. S., Carbone, S. E., Cao, E., Gondin, A. B., Veldhuis, N. A., Poole, D. P.. 2025-11-29. TRPV4 Promotes Histamine Receptor Signaling in Lymphatic Endothelial Cells. https://doi.org/10.1101/2025.11.25.690563

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Denaturation-sensitive BRET probes enable intracellular thermal shift measurements across diverse protein targets and biomolecular complexes

Thermal shift assays have revolutionized drug discovery, but can be limited in sensitivity and scalability. Combining the unique attributes of differential scanning fluorimetry (DSF) and cellular thermal shift (CETSA), we report the methodological framework for the bioluminescence resonance energy transfer shift assay (BRETSA). BRETSA utilizes denaturation sensitive BRET probes, in combination with luciferase-tagged target proteins, to track and longitudinally record thermal shift in living cells. Denaturation profiles were successfully measured for over 500 globular proteins, spanning 24 target families in diverse cellular compartments. Among these, target engagement was confirmed for over 200 proteins; including validated drug targets as well as understudied members of the kinase subfamily. Leveraging orthosteric, allosteric, and covalent ligands in potency studies, this method offers improved sensitivity and scalability compared to other thermal shift methods. We extend the utility of BRETSA to interrogate target engagement at biomolecular complexes and query cooperative binding for molecular glues and emerging tricomplex drug modalities.

pharmacology and toxicology↗

Peptide Sequence Determines the Efficacy of Single-Dose AAV-Vectorized GLP-1R Agonists in Diet-Induced Obese Mice

Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide produce substantial weight loss and glycemic improvement, but their long-term efficacy depends on sustained adherence to chronic dosing. Adeno-associated virus (AAV) gene therapy could, in principle, provide durable GLP-1R agonist (GLP-1RA) exposure from a single administration, but the degree of peptide engineering required for a vectorized GLP-1RA transgene to be efficacious in vivo is unknown. Methods: We generated four self-complementary AAV (scAAV) constructs encoding: native human GLP-1(7-36) (GLP-1), a DPP-IV-resistant Gly8-GLP-1(7-36) variant (Gly8), Exendin-4 (Ex4), or an Exendin-4 human IgG4 Fc fusion protein (Ex4-Fc). All four constructs were validated to secrete functional GLP-1R agonists in vitro using a conditioned-media potency assay. Subsequently, these constructs were packaged into PHP.eB capsids and administered as a single intravenous dose (5x1012 vg/kg) to diet-induced obese (DIO) mice alongside a vehicle control. Body weight, body composition, food intake, fasting plasma insulin, and oral glucose tolerance were assessed over a 3-week period. At the end of the study, tissues were harvested for assessments of plasma/liver lipids, tissue transgene transcript and peptide levels. Results: HEK293 cells transfected with the four AAV constructs all secreted active peptides/proteins as assessed by a cell-based GLP-1R activation assay, although the effective concentration of the GLP-1 constructs in the media spanned nearly four orders of magnitude 72 hours after transfection. In diet-induced obese (DIO) mice, Ex4 and Ex4-Fc vectors, but not GLP-1 or Gly8 vectors, produced significant reductions in body weight of up to 22.6% of starting body weight out to 21 days after a single dose. In addition, reductions in food intake, fat mass, and fasting insulin relative to vehicle were also observed for Ex4 and Ex4-Fc. Furthermore, Ex4-Fc improved oral glucose tolerance while reducing plasma cholesterol and liver triglycerides relative to vehicle. Although transcript levels did not differ appreciably among the four constructs in either brain or liver, measurable peptide product in plasma and brain lysate tracked the rank order of the in vitro supernatant screen, with GLP-1 and Gly8 groups indistinguishable from endogenous background. Conclusions: PHP.eB scAAV Ex4 and Ex4-Fc showed robust efficacy on multiple metabolic endpoints including weight loss and glucose tolerance. In contrast, vectorized GLP-1 and Gly8 showed no in vivo efficacy despite comparable levels of viral transcript in the brain and the liver. Vectorized GLP-1 and Gly8 also performed poorly compared to exendin-4-based constructs in vitro, suggesting that conditioned-media potency screening is a valid early filter for construct selection in vectorized-peptide AAV development. Engineering peptides to improve translation and secretion efficiency, in addition to circulating plasma stability, could further optimize vectorized GLP-1RA therapeutics.

pharmacology and toxicology↗

Preclinical Evaluation of a Novel BOC-Modified Triazoloacridinone (TRA-01AR) in Combination with 5-Fluorouracil in Colorectal Cancer

5-Fluorouracil (5-FU) remains a cornerstone of colorectal cancer (CRC) therapy, yet its clinical efficacy is limited by resistance, systemic toxicity, and unfavorable pharmacokinetics. Strategies that enhance tumor sensitivity while maintaining tolerability are therefore of considerable interest. Here, we evaluated 5-FU in combination with two triazoloacridinones, C-1305 and a novel BOC-modified derivative, TRA-01AR, using integrated cellular, transcriptomic, bioenergetic, and in vivo approaches. Both compounds induced cytotoxic effects across cancer cell models and produced overlapping but distinct transcriptional responses, primarily affecting DNA replication and cell cycle pathways. Bioenergetic profiling revealed a shift toward oxidative phosphorylation accompanied by reduced glycolysis, indicating modulation of cellular metabolism relevant to chemotherapy response. Interestingly, TRA-01AR exhibited delayed cytotoxicity relative to C-1305, although the underlying mechanism remains to be defined. In vivo, the combination of 5-FU with C-1305 significantly reduced tumor weight in HT-29 xenografts, whereas 5-FU combined with TRA-01AR did not result in a statistically significant reduction compared to 5-FU alone. TRA-01AR was associated with a more favorable systemic profile and increased intratumoral blood flow compared with C-1305. Collectively, these findings indicate that triazoloacridinones modulate transcriptional and metabolic programs relevant to the 5-FU response. While C-1305 demonstrated greater antitumor activity under the tested conditions, TRA-01AR exhibited distinct biological effects, including improved tolerability and vascular modulation. Further studies are required to clarify TRA-01AR's mechanism of action and assess its potential relevance in CRC-specific therapies.

pharmacology and toxicology↗